Search results
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via AOL· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
AbbVie (ABBV) Q1 Earnings Beat, Skyrizi Sales Underperform
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $2.46 per share for the first quarter of 2023,...
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
Zacks via Yahoo Finance· 10 months agoIn its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 2 weeks agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
AbbVie (ABBV) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 10 months agoAbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for...
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022,...
This Unstoppable Growth Stock Is Nearing a Once-In-a-Decade Buying Opportunity
Motley Fool· 1 year agoEven the most intrepid growth stocks experience doldrums, and such periods can be a great time to...
Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming?
Investor's Business Daily· 2 years agoAbbVie stock is under pressure after the company posted a mixed second-quarter report that relied...
Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks
Motley Fool· 2 years agoWith the market down by more than 21% in 2022, we're officially in a bear market, and many investors...